Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
Dr. Gardner brings over 30 years of experience leading clinical development to support innovative oncology programs and translational research at...
Cancer
Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"...
Introducing the Future of Histology: Groundbreaking 3D Viewer Unveiled to Reveal Tumor Spatial Characteristics
CHICAGO, IL / ACCESSWIRE / October 9, 2023 / Wision A.I., a cutting-edge software medical device startup, is proud to...
LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach
PASADENA, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW),...
Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
Mr. Garner brings over 25 years of pharmaceutical industry experienceTHE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals,...
Sensus Healthcare to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference
BOCA RATON, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of...
BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
- Early assessment of increased glycosylated ⍺DG levels at 3 months predicted subsequent ambulatory improvements at 9 months, supporting the...
RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer
SYDNEY, Australia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products...
Defence to Present Three of Its Leading Products at the Upcoming Festival of Biologics in Basel, Switzerland
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"...
IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board
Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON’s FixPlas™ and Indiplas™ modalities in immuno-oncology. LAWRENCEVILLE, N.J.,...
Immunocore announces upcoming presentation and posters at ESMO 2023
Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic...
US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix
LONDON and SALT LAKE CITY, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company...
Janssen Submits Application to the European Medicines Agency for RYBREVANT®▼ (amivantamab) in Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon 20 Insertion Mutations
Type II Extension of Indication Application is supported by data from PAPILLON, the first randomised Phase 3 study to read...
Sequana Medical announces Extraordinary General Meeting of Shareholders on 10 November 2023
PRESS RELEASEREGULATED INFORMATION06 October 2023, 07:00 am CEST Ghent, Belgium – 06 October 2023 – Sequana Medical NV (Euronext...
Landmark studies utilizing Olink® Explore technology signal a new era for population-scale proteogenomics
UPPSALA, Sweden, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today reported the publication of three...
Kineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused...
Tenth Patient With Depression Starts Dosing MB22001 in Take Home Microdosing Trials
VANCOUVER, BC / ACCESSWIRE / October 5, 2023 / MindBio Therapeutics Corp. (CSE:MBIO);(Frankfurt:WF6), (the "Company" or "MindBio"), is pleased to...
GE HealthCare and University Hospitals Enter 10-Year Strategic Collaboration to Contemporize Its Imaging Fleet and Implement Enterprise Digital Solutions to Help Improve Patient Care and Optimize Processes
Technology-powered collaboration aims to deliver AI-enabled devices and digital solutions at the enterprise level to increase clinical and operational efficiencies,...
New York-Based FQHC Reports 20% Improvement in Patients Controlling High Blood Pressure and a 17% Increase in Depression Screening Utilizing eClinicalWorks
Betances Health Center establishes standardization and combats physician burnout with eClinicalWorks EHRWESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, the largest ambulatory cloud EHR, today...